Goflikicept PREVENTS recurrence and MAINTAINS remission in idiopathic recurrent pericarditis patients
An Original Investigation by Dr Valentina Yu. Myachikova, published in the Journal of the American College of Cardiology, has demonstrated the benefits of Goflikicept in idiopathic recurrent pericarditis. This anti-cytokine biologic prevents recurrence and maintains IRP remission with a favourable risk-benefit ratio, as described in the study.
It is already known that IRP is a rare autoinflammatory disease. Interleukin (IL)-1α and IL-1β are the pivotal cytokines in the pathophysiology of acute pericarditis. These are involved in its recurrence also.
In the present study, the team created a phase II/III study with a new IL-1 inhibitor—goflikicept in IRP and evaluated its safety and efficacy in treating IRP patients in their 2-centre open-label study.
The study had four periods: screening, run-in, randomized withdrawal, and follow-up.
The study results could be summarised as follows:
- Twenty-two patients were enrolled, and 20 were randomized.
- During the run-in period, results demonstrated a reduction of C-reactive protein level accompanied by a reduction of chest pain and pericardial effusion compared to baseline.
- There was a Recurrence of pericarditis in 9/10 patients in the placebo group.
- Researchers reported no recurrence events in the goflikicept group within 24 weeks following randomization.
- A total of 122 adverse events were reported in 21 patients (95.5%), with no deaths and no new safety signals identified for goflikicept.
They said goflikicept prevents recurrences and maintains IRP remission with a favourable risk-benefit ratio. Goflikicept reduced the risk of recurrence compared with the placebo.
Further reading:
